Marshall Wace, LLP 4 D Molecular Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
A detailed history of Marshall Wace, LLP transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 165,193 shares of FDMT stock, worth $756,583. This represents 0.0% of its overall portfolio holdings.
Number of Shares
165,193
Previous 185,866
11.12%
Holding current value
$756,583
Previous $3.9 Million
54.24%
% of portfolio
0.0%
Previous 0.01%
Shares
10 transactions
Others Institutions Holding FDMT
# of Institutions
145Shares Held
56.8MCall Options Held
137KPut Options Held
111K-
Bvf Inc San Francisco, CA7.38MShares$33.8 Million2.54% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.1MShares$23.3 Million0.77% of portfolio
-
Black Rock Inc. New York, NY4.9MShares$22.4 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY4.4MShares$20.2 Million4.93% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.1MShares$18.8 Million1.63% of portfolio
About 4D Molecular Therapeutics, Inc.
- Ticker FDMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,382,400
- Market Cap $148M
- Description
- 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...